Heparin prevents the blood from clotting and is used to treat and prevent deep vein thrombosis and pulmonary embolism. It is also used as part of the treatment of myocardial infarction and unstable angina. Another application of heparin is an inner surface anticoagulant on various experimental and medical devices such as test tubes and renal dialysis machines.
Crude heparin is the starting material intended for further processing by FDA drug establishments into heparin sodium USP API (active pharmaceutical ingredient), not a finished drug product. The scope of this report is mainly about Crude Heparin, Crude heparin is the upstream raw material for heparin.
The global Crude Heparin market
is valued at USD 2094.48 million in 2018 and is expected to reach USD 6645.61 million by the end of 2025, growing at a CAGR of 14.94% between 2019 and 2025. Overall, the Crude Heparin products performance is positive with the current environment status.
Currently, there are many players in this market. Shenzhen Hepalink, Pharma Action (T?nnies Group), Fengrun Biological, Nanjing King-friend, Hebei Changshan Biochemical and some others are playing important roles in Crude Heparin industry. The market is dispersed for now and is seeing to be more concentrated in the future.
In market, revenue of Crude Heparin in China will increase to be 4093 M USD in 2025 from 1118 M USD in 2018, which is the biggest area in current market pattern. North America ranks the second largest area, with sales revenue and market share of 455 M USD in 2018.
There are two different types of Crude Heparin. The market can be segmented into: Pig Intestine Mucosa Heparin, Bovine Heparin and Others. Pig Intestine Mucosa Heparin is almost the only used and efficient types and took 99.6% market share in 2018. By application, LMWH is the largest consumer group, with market share of 89% in 2018.
Companies are focusing on technological innovation, equipment upgrades, and process improvements, to reduce costs and improve quality. The total competition market for Crude Heparin will become more intense, while the market is going to be more concentrated in the future.